{
  "symbol": "AMGN",
  "year": 2022,
  "period": "Q2",
  "curated_text": "Symbol: AMGN. Year: 2022. Period: Q2. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Authority, the Condensed Consolidated Balance Sheets, ROW, ROW Total U.S. ROW Total, Company. Context excerpt: petition Authority. As of June 30, 2022, held-for-sale assets and liabilities of $ 100 million and $ 20 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $ 560 million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuation allowances to Other current assets and Accrued liabilities in the Condensed Consolidated Balance Sheets. 9 3. Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers\u2019 locations, are presented below. The majority of ROW revenues relates to products sold in Europe. Reven",
  "competition_summary": [
    {
      "competitor": "Authority",
      "mentions": 1,
      "context": "petition Authority. As of June 30, 2022, held-for-sale assets and liabilities of $ 100 million and $ 20 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $ 560 million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuati"
    },
    {
      "competitor": "the Condensed Consolidated Balance Sheets",
      "mentions": 2,
      "context": "petition Authority. As of June 30, 2022, held-for-sale assets and liabilities of $ 100 million and $ 20 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $ 560 million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuati"
    },
    {
      "competitor": "ROW",
      "mentions": 1,
      "context": "petition Authority. As of June 30, 2022, held-for-sale assets and liabilities of $ 100 million and $ 20 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $ 560 million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuati"
    },
    {
      "competitor": "ROW Total U.S. ROW Total",
      "mentions": 2,
      "context": "petition Authority. As of June 30, 2022, held-for-sale assets and liabilities of $ 100 million and $ 20 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $ 560 million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuati"
    },
    {
      "competitor": "Company",
      "mentions": 2,
      "context": "petition Authority. As of June 30, 2022, held-for-sale assets and liabilities of $ 100 million and $ 20 million were included in Other current assets and Accrued liabilities, respectively, in the Condensed Consolidated Balance Sheets. During the three months ended June 30, 2022, we recognized a loss of $ 560 million recorded to Other operating expenses in the Condensed Consolidated Statements of Income, primarily due to the impact of the cumulative foreign currency translation loss, with valuati"
    }
  ]
}